<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-Z4ZG78N5</identifier><date>2020</date><creator>Bratkovič, Tomaž</creator><creator>Lovšin, Nika</creator><creator>Lunder, Mojca</creator><relation>documents/doc/Z/URN_NBN_SI_doc-Z4ZG78N5_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-Z4ZG78N5_001.txt</relation><format format_type="issue">2</format><format format_type="volume">71</format><format format_type="type">article</format><format format_type="extent">str. 163-173</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">20559875</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-Z4ZG78N5</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Cepiva</subject><subject language_type_id="slv">pandemija covid-19</subject><subject language_type_id="slv">Pandemije</subject><subject language_type_id="slv">SARS-CoV-2</subject><title>Razvoj cepiv proti virusu SARS-CoV-2</title><title>SARS-CoV-2 vaccine pipeline</title></Record>